Abstract
Background/purpose: The etiology of portal hypertension may be an important factor affecting patient outcomes after transjugular intrahepatic portosystemic shunt (TIPS) treatment. Pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is characterized by acute portal hypertension and liver injury. This study compared post-TIPS survival between patients with PA-HSOS and those with other etiologies of hepatic portal hypertension.
Methods: A retrospective review of 787 patients with portal hypertension-related complications (including 146 with PA-HSOS) treated with TIPS between 2008 and 2020 was performed. Propensity score matching (PSM) was used to minimize bias.
Results: PA-HSOS patients initially presented with higher Child-Pugh and MELD scores. However, after PSM, OLT-free survival was significantly better in PA-HSOS patients than in those with viral hepatitis, primary biliary cirrhosis, autoimmune hepatitis, or schistosomiasis.
Conclusions: TIPS is safe for PA-HSOS patients, who often show better or similar prognosis compared to other etiologies.
Introduction
Hepatic Sinusoidal Obstruction Syndrome (HSOS) is a rare, life-threatening vascular liver disease. In China, it is frequently linked to the ingestion of "Tusanqi" (Gynura segetum), a medicinal herb containing toxic pyrrolizidine alkaloids (PAs). These toxins cause acute blockage of small liver veins, leading to rapid-onset portal hypertension and liver failure. While Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement is a recognized intervention to relieve portal pressure, the long-term outcomes for PA-HSOS patients compared to those with more common causes of portal hypertension, such as viral hepatitis or alcoholic cirrhosis, have remained unclear.
Methods
This retrospective study analyzed 787 patients treated at Nanjing Drum Tower Hospital from August 2008 to September 2020. The cohort included 146 patients with PA-HSOS and 641 patients with other etiologies (HBV, HCV, Alcohol, PBC, AIH, Schistosomiasis, etc.).
To ensure a rigorous comparison, researchers employed Propensity Score Matching (PSM). This statistical method matched patients across groups based on age, sex, and baseline disease severity (MELD and Child-Pugh scores), effectively controlling for selection bias and allowing for a more accurate assessment of how disease etiology influences survival.
Results
The study revealed a "Sicker but Stronger" paradox. At the time of the procedure, PA-HSOS patients exhibited significantly higher MELD and Child-Pugh scores compared to other groups, indicating more severe initial liver dysfunction.
However, post-TIPS outcomes told a different story. Before matching, overall survival was comparable across groups. After PSM, PA-HSOS patients demonstrated significantly superior orthotopic liver transplantation (OLT)-free survival compared to:
- Viral Hepatitis (HBV/HCV): $P = 0.0011$
- Autoimmune/Biliary Cirrhosis (PBC/AIH): $P = 0.021$
- Schistosomiasis: $P = 0.025$
The safety profile of TIPS in PA-HSOS was robust, with a 1-year survival rate of approximately 86.5%.
Discussion
The superior survival of PA-HSOS patients despite higher initial severity likely stems from the nature of the pathology. PA-HSOS is an acute vascular insult. Once the mechanical obstruction is bypassed via TIPS and the toxic source is removed, the liver retains a high capacity for regeneration. In contrast, etiologies like Hepatitis B or PBC involve chronic inflammation and irreversible scarring (cirrhosis), which limits the liver's ability to recover even after portal pressure is reduced.
A critical finding was the timing of intervention. Eleven PA-HSOS patients died within one month of the procedure, primarily due to multi-organ failure. This suggests that while TIPS is a highly effective salvage therapy, it must be performed before systemic deterioration becomes irreversible.
Conclusion
TIPS placement is a safe and effective treatment for patients with PA-HSOS. Despite presenting with more severe clinical markers initially, these patients often achieve better long-term survival than those with chronic cirrhotic conditions. Future prospective, multicenter trials are needed to further optimize the timing of TIPS for toxic liver injuries.
Limitations: This study was retrospective and conducted at a single center, which may limit the generalizability of the findings. Shunt dysfunction and encephalopathy rates were not tracked in detail.
Summary updated